Neoplasms

Skin and Connective Tissue Diseases

All Conditions

Symptoms and General Pathology

Breast Neoplasms

Alopecia

Alopecia Areata

Hypotrichosis

Hair Diseases

Skin Diseases

Pathological Conditions, Anatomical

Antineoplastic Agents

Antirheumatic Agents

All Drugs and Chemicals

Cyclophosphamide

Epirubicin

All patients will undergo photobiomodulation therapy sessions three times a week for the total duration of 12 weeks starting at their last CT administration.

Photobiomodulation therapy

Jeroen Mebis, prof. dr.

Joy Lodewijckx, drs.

Jeroen Mebis, prof.dr.

Chemotherapy (CT) remains an important treatment modality for breast cancer patients. Unfortunately, this systemic treatment comes with many quality of life impairing complications. Chemotherapy-induced alopecia (CIA) occurs in about 65% of the patients. Hair loss due to CT is reversible, but hair regrowth requires several months to a year after CT. Currently, the only available preventive measure is based on scalp cooling. Nevertheless, this treatment has a highly variable success rate and it brings along several side effects. Photobiomodulation therapy (PBMT) is a new, preventive and therapeutic technique in the supportive care of cancer patients. It uses visible and (near)- infrared light produced by laser diodes or light-emitting diodes (LED) at a low power to stimulate tissue repair and reduce inflammation and pain. The investigator's research team demonstrated already that PBMT can prevent oral mucositis and acute radiodermatitis. The aim of this project is to explore the use of PBMT in the management of CIA. Results of this project will lead to an improvement of the patients' quality of life after CT.

PBMT for the Management of CIA ( HAIRLASER )

Photobiomodulation Therapy for the Management of Chemotherapy-induced Alopecia: a Randomized, Placebo-controlled Feasibility Trial

A mechanical visual analogue scale (VAS) will be used to evaluate the patients' hair regrowth based on photographs taken at the four time points. The patients will be asked to indicate their subjective experience of hair regrowth. This score is associated with a certain score, in which 0 = 'total baldness' and 10 = 'full scalp coverage'.

A validated questionnaire of the European Organization for Research and Treatment-QOL questionnaire and breast cancer specific module

The patients' global satisfaction with the PBMT/sham therapy will be evaluated using a numerical rating scale (NRS) from 0 (minimum score) to 10 (maximum score)

Jessa Hospital

Hasselt University

Principal Investigator

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
PBMT for the Management of CIA ( HAIRLASER )	NCT04036994	Breast Cancer Chemotherapy-in... Alopecia	Photobiomodulat...	18 Years -	Hasselt University
PBMT for the Management of CIA ( HAIRLASER )	NCT04036994	Breast Cancer Chemotherapy-in... Alopecia	Photobiomodulat...	18 Years -	Hasselt University

Spots Global Cancer Trial Database for epirubicin cyclophosphamide